The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates

被引：95

作者：

Kaiser-Guignard, Julie ^{[1
]}

Canellini, Giorgia ^{[2
]}

Lion, Niels ^{[2
]}

Abonnenc, Melanie ^{[2
]}

Osselaer, Jean-Claude ^{[2
]}

Tissot, Jean-Daniel ^{[2
]}

机构：

[1] CHU Vaudois, Serv Hematol, CH-1011 Lausanne, Switzerland

[2] Serv Reg Vaudois Transfus, CH-1066 Epalinges, Switzerland

来源：

BLOOD REVIEWS | 2014年 / 28卷 / 06期

关键词：

Amotosalen; Hemovigilance; Pathogen inactivation; Pathogen reduction; Platelets; Platelet concentrates; Riboflavin; Transfusion; IN-VITRO EVALUATION; INTERSTRAND CROSS-LINKS; INTERCEPT BLOOD SYSTEM; THERAPEUTIC-EFFICACY; FUNCTIONAL-CHARACTERISTICS; PHOTOCHEMICAL TREATMENT; AMOTOSALEN-HCL; BLEEDING COMPLICATIONS; PROTEIN-SYNTHESIS; ADDITIVE SOLUTION;

D O I：

10.1016/j.blre.2014.07.005

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Since 1990, several techniques have been developed to photochemically inactivate pathogens in platelet concentrates, potentially leading to safer transfusion therapy. The three most common methods are amotosalen/UVA (INTERCEPT Blood System), riboflavin/UVA-UVB (MIRASOL PRT), and UVC (Theraflex-UV). We review the biology of pathogen inactivation methods, present their efficacy in reducing pathogens, discuss their impact on the functional aspects of treated platelets, and review clinical studies showing the clinical efficiency of the pathogen inactivation methods and their possible toxicity. (C) 2014 The Authors. Published by Elsevier Ltd.

引用

页码：235 / 241

页数：7